Glucotrack appoints David S. Hirsh, MD as Medical Director, Cardiology

Glucotrack, Inc.

Dr. Hirsh, a cardiac electrophysiologist, joins Glucotrack's clinical advisory team for its CBGM program.
He will oversee clinical and educational initiatives supporting the CBGM's intravascular placement approach.
Glucotrack is advancing its CBGM through a long-term OUS early feasibility study and upcoming US pilot study.
CBGM is a long-term implantable system measuring glucose directly from blood, with up to 3-year sensor life.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.